Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 3/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357232 | 1.00 | CTSK (0.48) | CTSKPARP1TNKS2PARP2F12 | |
| SCHEMBL21588265 | 0.91 | PARP1 (0.49) | PARP1TNKS2PARP2F12ESR2 | |
| SCHEMBL29292243 | 0.90 | DDB1 (0.41) | CTSKPARP1TNKS2PARP2F12 | |
| SCHEMBL21630707 | 0.88 | CFTR (0.56) | PARP1TNKS2PARP2F12CFTR | |
| SCHEMBL6482451 | 0.85 | PARP1 (0.44) | CTSKPARP1TNKS2PARP2F12 | |
| SCHEMBL8103406 | 0.83 | F12 (0.44) | PARP1TNKS2PARP2F12CFTR | |
| SCHEMBL21154244 | 0.82 | CFTR (0.56) | PARP1TNKS2PARP2F12CFTR | |
| SCHEMBL21121029 | 0.82 | CTSK (0.53) | CTSKCFTRLMNABAZ2BMAPT | |
| SCHEMBL29357331 | 0.81 | MAPT (0.69) | CFTRLMNABAZ2BMAPTPABPC1 | |
| SCHEMBL2241936 | 0.81 | MAPT (0.69) | CFTRLMNABAZ2BMAPTPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2022-04-28 | — | — | US | disclosed |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2022-04-28 | — | — | US | disclosed |
| CN-113453688-A | Novel compounds for treating, reducing or preventing conditions associated with Tau aggregates | AC免疫有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-111757882-A | 1,3,4, 5-tetrahydro-2H-pyrido [4,3-b ] indole derivatives for the treatment, alleviation or prevention of disorders associated with Tau aggregates such as alzheimer's disease | AC免疫有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2019134978-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC IMMUNE SA (CH) | 2019-07-11 | — | — | WO | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | CTSK 2166/4885PARP1 2974/4885TNKS2 1445/4885 |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | CTSK 2166/4885PARP1 2974/4885TNKS2 1445/4885 |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | CTSK 2071/4885PARP1 2941/4885TNKS2 1621/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | CTSK 2166/4885PARP1 2974/4885TNKS2 1445/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | CTSK 2071/4885PARP1 2941/4885TNKS2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.